NEC Corp (6701.T)

6701.T on Tokyo Stock Exchange

369JPY
29 Jul 2015
Change (% chg)

-- (--)
Prev Close
¥369
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17,391,783
52-wk High
¥430
52-wk Low
¥319

6701.T

Chart for 6701.T

About

NEC Corporation is a diversified company. The Platform segment provides system integration, supporting, outsourcing and cloud services, among others to government, public, medical, financial and media industries. The Enterprise segment provides system integration, supporting, outsourcing and cloud services, among others to... (more)

Overall

Beta: 1.19
Market Cap(Mil.): ¥963,751.12
Shares Outstanding(Mil.): 2,604.73
Dividend: --
Yield (%): 1.08

Financials

  6701.T Industry Sector
P/E (TTM): 16.78 24.97 17.29
EPS (TTM): 22.05 -- --
ROI: 3.81 10.70 10.29
ROE: 7.54 11.88 7.46
Search Stocks

UPDATE 1-Nigeria's oil company kept nearly half of oil revenue - NEC

* President Buhari elected on anti-graft ticket (Adds quotes, detail, background)

29 Jun 2015

TABLE-NEC -2014/15 parent results

Apr 28 - NEC Corp PARENT-ONLY FINANCIAL HIGHLIGHTS (in billions of yen unless specified) Year ended Year ended Year to NEXT Mar 31, 2015 Mar 31, 2014 Mar 31, 2016 YEAR LATEST YEAR-AGO COMPANY COMPANY RESULTS RESULTS FORECAST H1 FORECAST Sales 1.92 trln 1.90 trln

28 Apr 2015

TABLE-NEC -2014/15 group results

Apr 28 - NEC Corp CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) Year ended Year ended Year to NEXT Mar 31, 2015 Mar 31, 2014 Mar 31, 2016 YEAR LATEST YEAR-AGO COMPANY COMPANY RESULTS RESULTS FORECAST H1 FORECAST Sales 2.94 trln 3.04 trln 3.10 trln

28 Apr 2015

TABLE-NEC -2014/15 group forecast

Apr 24 - NEC Corp CONSOLIDATED EARNINGS ESTIMATES (in billions of yen unless specified) Full Year to Full Year to Mar 31, 2015 Mar 31, 2015 LATEST PREVIOUS FORECAST FORECAST Sales 2.94 trln 3.00 trln Operating 128.00 120.00 Recurring 112.00 90.00 Ne

24 Apr 2015

BRIEF-Biogaia subsidiary gets Orphan drug designation in Europe

* Biogaia subsidiary infant bacterial therapeutics gets orphan drug designation in europe

23 Feb 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks